Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular pathways that modify tumor radiation response.

M Pervan1, F Pajonk, J R Sun

  • 1Department of Radiation Oncology, Roy E. Coats Research Laboratories and Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, CA 90095-1714, USA.

American Journal of Clinical Oncology
|October 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticancer potential of ethanolic <i>Bacopa monnieri</i> L. extract: induction of intrinsic apoptosis in A549 lung cancer cells.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2026
Same author

Image Gallery: A case of porokeratosis ptychotropica.

The British journal of dermatology·2019
Same author

Image Gallery: Malignant syphilis in a young man with HIV infection.

The British journal of dermatology·2018
Same author

[Inflammatory and immune biomarkers of radiation response].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2018
Same author

Direct observation of the topological spin configurations mediated by the substitution of rare-earth element Y in MnNiGa alloy.

Nanoscale·2018
Same author

A pinhole camera for ultrahigh-intensity laser plasma experiments.

The Review of scientific instruments·2017
Same journal

Care Patterns and Gastric Cancer-Related Outcomes in Patients With Pathogenic/Likely Pathogenic Germline CDH1 Variants: A 14-Year Single-Center Analysis.

American journal of clinical oncology·2026
Same journal

Upper Extremity Lymphedema​​​: Performance of a Risk Prediction Model in Women Undergoing Surgery for Breast Cancer.

American journal of clinical oncology·2026
Same journal

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO).

American journal of clinical oncology·2026
Same journal

Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach.

American journal of clinical oncology·2026
Same journal

Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States.

American journal of clinical oncology·2026
Same journal

Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery: A Real-World Cohort Study.

American journal of clinical oncology·2026
See all related articles

Proteasome inhibitors like PS-341 show promise as novel cancer treatments. This study demonstrates that inhibiting the proteasome can enhance radiosensitivity and directly combat tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aberrant signaling pathways controlling cell fate are hallmarks of cancer.
  • Targeting these pathways offers tumor-specific strategies and potential radiosensitization.
  • Tumor heterogeneity can limit the efficacy of targeted therapies.

Purpose of the Study:

  • To investigate the ubiquitin/proteasome degradation pathway as a global mechanism for cancer control.
  • To evaluate the effects of proteasome inhibition on cellular radiosensitivity and antitumor activity.

Main Methods:

  • Utilized PS-341, a reversible proteasome inhibitor.
  • Assessed cellular radiosensitivity in vitro and in vivo.
  • Evaluated direct antitumor effects of proteasome inhibition.

Related Experiment Videos

Main Results:

  • Proteasome inhibition by PS-341 altered cellular radiosensitivity.
  • PS-341 demonstrated direct antitumor effects.
  • The ubiquitin/proteasome pathway is a viable target for cancer therapeutics.

Conclusions:

  • Targeting the ubiquitin/proteasome pathway offers a robust strategy against cancer.
  • Proteasome inhibitors like PS-341 have potential as anticancer drugs, enhancing radiation therapy.
  • Further clinical investigation of proteasome inhibitors is warranted.